{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Serious Adverse Event Reporting to Alexion or Designee via the RAVE Safety Gateway', 'As soon as the EDC becomes available, the data should be entered in the eCRF and forwarded to', 'Alexion GPV via the RAVE Safety Gateway.', 'When further information becomes available, the eCRF should be updated with the new', 'information and an updated SAE report should be submitted to Alexion GPV via the RAVE Safety', 'Gateway.', 'After the study is completed at a given site, the EDC will be taken offline to prevent the entry of', 'new data or changes to existing data.', 'If', 'a site identifies a new SAE from a study patient or receives updated data on a previously', 'reported SAE after the electronic data collection tool has been taken offline, then the site', 'can', 'report this information on a paper SAE form to Alexion GPV.', 'SAE Reporting to Alexion or Designee via Paper Contingency Case Report Form', 'If applicable, additional information such as relevant medical records should be submitted to', 'Alexion GPV via the email address or facsimile number noted above.', 'All paper forms and follow-up information submitted to the Sponsor outside of the RAVE Safety', 'Gateway (eg, discharge summary) should be kept in the appropriate section of the study file.', 'Page 77 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', '10.4.1.', 'Contraception Guidance', 'Before receiving study drug, female patients who consider themselves to be postmenopausal', 'must provide evidence of menopause based on a combination of amenorrhea for at least 1 year', 'and increased serum follicle-stimulating hormone level (> 30 IU/L).', 'Patients of childbearing potential must use a highly effective or acceptable method of', 'contraception (as defined below) starting at Screening and continuing for at least 8 months after', 'the last dose of study drug.', 'Highly effective contraceptive methods include:', '1. Hormonal contraception associated with inhibition of ovulation', '2. Intrauterine device', '3. Intrauterine hormone-releasing system', '4. Bilateral tubal occlusion', '5.', \"Vasectomized partner provided that the partner is the patient's sole sexual partner\", '6. Sexual abstinence defined as refraining from heterosexual intercourse during the entire', 'period of risk associated with the study drug treatment; reliability of sexual abstinence', 'needs to be evaluated in relation to the duration of the clinical study and the preferred and', 'usual lifestyle of the patient', 'Acceptable contraceptive methods include:', '7. A combination of male condom with either cap, diaphragm, or sponge with spermicide', '(double barrier methods)', 'The above-listed method(s) of contraception chosen for an individual patient can be determined', \"by the Investigator with consideration for the patient's medical history and concomitant\", 'medications.', 'Patients with a spouse/partner of childbearing potential or a pregnant or breastfeeding spouse or', 'partner must agree to use double barrier contraception (male condom plus appropriate barrier', 'method for the female partner) while on treatment and for at least 8 months after the last dose of', 'study drug. Double barrier contraception is required even with documented medical assessment', 'of surgical success of a vasectomy.', 'Male patients must not donate sperm and female patients must not donate ova while on treatment', 'and for at least 8 months after the last dose of study drug.', '10.4.2.', 'Pregnancy Testing', 'Patients of childbearing potential should only be included after a menstrual period and a negative', 'highly sensitive serum pregnancy test.', 'Additional pregnancy testing should be performed per the time points specified in the SoA', '(Section 1.3).', 'Page 78 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is', 'otherwise suspected.', '10.4.3.', 'Collection and Reporting of Pregnancy Information', 'No studies of ALXN1210 have been conducted in pregnant women. Pregnant or nursing female', 'patients are excluded from the study. Patients enrolled in the study, and a spouse or partner, will', 'use a highly effective or acceptable method of contraception.', 'In the event of a pregnancy event, pregnancy data will be collected during this study for all', 'patients and a female spouse/partner of male patients. Exposure during pregnancy (also referred', 'to as exposure in utero) can be the result of either maternal exposure or transmission of drug', 'product via semen following paternal exposure. For all Alexion products, both in development or', 'postapproval, exposure during pregnancy must be recorded and the pregnancy followed until the', 'outcome of the pregnancy is known (ie, spontaneous miscarriage, elective termination, normal', 'birth, or congenital abnormality), even if the patient discontinues study drug or withdraws from', 'the study.', \"If a female patient or a patient's female partner becomes pregnant during the conduct of this\", 'study, the Investigator must submit the \"Pregnancy Reporting and Outcome/Breastfeeding\" form', 'to Alexion GPV via facsimile or email (Section 10.3). When the outcome of the pregnancy', 'becomes known, the form should be updated and submitted to Alexion GPV. If additional', 'follow-up is required, the Investigator will be requested to provide the information.', 'Exposure of an infant to an Alexion product during breastfeeding must also be reported (via the', '\"Pregnancy Reporting and Outcome Form/Breastfeeding\" form) and any AEs experienced by the', 'infant must be reported to Alexion GPV or designee via email or facsimile (Section 10.3).', 'Pregnancy in itself is not regarded as an AE unless there is a suspicion that the investigational', 'product may have interfered with the effectiveness of a contraceptive medication. However,', 'complications of pregnancy and abnormal outcomes of pregnancy are AEs and may meet the', 'criteria for an SAE (eg, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise,', 'neonatal death, or congenital anomaly). Elective abortions without complications should not be', 'reported as AEs.', 'Page 79 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}